Call  +41 61 926 6040
Fax +41 61 926 6049
Toggle Nav
My Cart
Search
Advanced Search
Account
Settings

Proteins

Toggle Nav

Items 1-10 of 13

Page
per page
Set Descending Direction
  1. ANGPTL7 (human) (rec.)
    AG-40A-0060
    AG-40A-0060-C01010 µg
    CHF 265.00
    AG-40A-0060-C05050 µg
    CHF 790.00
    Add to Compare
    Learn More
    ERK phosphorylation induced by hANGPTL7 in THP-1 cells. THP-1 monocyte cells were serum starved for 16hr and then stimulated with ANGPTL7 (human) (rec.) (Prod. No. AG-40A-0060) (500ng/ml) for 1, 2 and 3 hrs, respectively. Antibodies against pERK1/2
  2. DLL1 (human) (rec.)
    AG-40A-0073
    AG-40A-0073-C01010 µg
    CHF 190.00
    AG-40A-0073-C05050 µg
    CHF 380.00
    Add to Compare
    Learn More
    Adipogenesis inhibition of MSCs. MSCs (Mesenchymal stem cells) were maintained in DMEM, supplemented with 10% fetal bovine serum, penicilin-streptomycin and glutamine. For differentiation of MSCs, MSCs were cultured in adipogenic medium which was gr
  3. DLL1 (human):Fc (human) (rec.)
    AG-40A-0116Y
    AG-40A-0116Y-C01010 µg
    CHF 305.00
    AG-40A-0116Y-C05050 µg
    CHF 835.00
    Add to Compare
    Learn More
    Adipogenesis inhibition of 3T3L1 cells.3T3L1 cells were maintained in DMEM, supplemented with 10% fetal bovine serum, penicilin-streptomycin. Adipogenesis was initiated by adding 1μM dexamethasone, 0.5mM IBMX, 10μg/ml insulin (day 0) until day
  4. DLL4 (human):Fc (human) (rec.) (highly active mutant)
    AG-40B-0176
    AG-40B-0176-C01010 µg
    CHF 350.00
    AG-40B-0176-C100100 µg
    CHF 1'080.00
    Add to Compare
    Learn More
    DLL4 (human):Fc (human) (rec.) (highly active mutant) (AG-40B-0176) binds to mNotch1 with higher affinity than WT DLL4:Fc. Method: Notch1 (mouse):Fc was coated on an ELISA plate at 1μg/ml. After blocking and washing steps, indicated concentrations
  5. Fc (human):FLT3 Ligand (human) (rec.)
    AG-40B-0119
    AG-40B-0119-C01010 µg
    CHF 240.00
    AG-40B-0119-30103 x 10 µg
    CHF 480.00
    AG-40B-0119-C100100 µg
    CHF 960.00
    Add to Compare
    Learn More
    Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 μg daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice.
  6. FGF-2 (human) (rec.) (untagged)
    AG-40B-0150
    AG-40B-0150-C01010 µg
    CHF 120.00
    AG-40B-0150-30103 x 10 µg
    CHF 240.00
    Add to Compare
    Learn More
  7. Frizzled-5 (human):Fc (human) (rec.)
    AG-40B-0133
    AG-40B-0133-C05050 µg
    CHF 290.00
    AG-40B-0133-30503 x 50 µg
    CHF 575.00
    Add to Compare
    Learn More
    Figure: Frizzled-5 (human):Fc (human) (rec.) (AG-40B-0133) efficiently inhibits Wnt3a activation. Methods: Inhibition of Wnt3a activation by Frizzled-5 (human):Fc (human) (rec.) was measured by using HEK293 cells transfected with a plasmid c
  8. LIF (human) (rec.)
    AG-40B-0093
    AG-40B-0093-C01010 µg
    CHF 170.00
    AG-40B-0093-30103 x 10 µg
    CHF 335.00
    AG-40B-0093-C100100 µg
    CHF 1'010.00
    Add to Compare
    Learn More
    Figure: Human Leukemia Inhibitory Factor (LIF) (rec.) (AG-40B-0093) maintains pluripotency of mouse ES cells. Method: Mouse ES oct4 GFP cells were cultured for 3 days in the presence of the indicated concentrations of LIF and followed
  9. MFAP4 (human) (rec.)
    AG-40A-0072
    AG-40A-0072-C01010 µg
    CHF 215.00
    AG-40A-0072-C05050 µg
    CHF 540.00
    Add to Compare
    Learn More
  10. Netrin-1 (human) (rec.)
    AG-40B-0040
    AG-40B-0040-C01010 µg
    CHF 300.00
    AG-40B-0040-30103 x 10 µg
    CHF 600.00
    AG-40B-0040-C100100 µg
    CHF 1'320.00
    Add to Compare
    Learn More

Items 1-10 of 13

Page
per page
Set Descending Direction
Shop By
Active Filters
  1. Product Line / Research Area Stem Cell Research Remove This Item
  2. Crossreactivity Human Remove This Item
  3. Brand AdipoGen Life Sciences Remove This Item
Clear All
Search Filter
Product Type
  1. Protein 13 items
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.